4 recruiting, 2 completed, 1 unknown. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow ATTR Amyloidosis: new trials by email Literature Review of ATTR Amyloidosis trials Research Report on ATTR Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hungarian National Systemic Amyloidosis Registry Systemic Amyloidosis, ATTR Amyloidosis | Recruiting | Semmelweis University | 300 | 2026-03-08 | 2026-07-08 | |
| Orthopaedic Specimen Pathology and Early Diagnosis of ATTR Cardiopathy (ATTR-ORTHO) ATTR Amyloidosis, Cardiopathy | Unknown | Institut Mutualiste Montsouris | 150 | 2024-02-27 | 2024-04-16 | |
| OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis no intervention - ATTR Amyloidosis | Recruiting | AstraZeneca | 52121 | 2023-08-21 | 2026-09-09 | |
| Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis [18F]florbetaben - Cardiac Amyloidosis, AL Amyloidosis | Phase 3 | Completed | Lantheus Germany GmbH | 244 | 2023-01-13 | 2026-08-03 |
| The Italian Transthyretin Amyloidosis Web-Network ATTR Amyloidosis | Recruiting | Fondazione IRCCS Policlinico San Matteo di Pavia | 1000 | 2022-07-13 | 2026-03-27 | |
| ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis | Recruiting | Alnylam Pharmaceuticals | 1500 | 2020-11-23 | 2026-10-13 | |
| The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant Revusiran - Transthyretin (TTR)-Mediated Amyloidosis, Familial Amyloidotic Polyneuropathy (FAP) | Phase 2 | Completed | Alnylam Pharmaceuticals | 12 | 2015-10-01 | 2019-03-28 |
Amyloid Neuropathies, Familial (5) · Immunoglobulin Light-chain Amyloidosis (3) · Amyloidosis (2) · Amyloid Neuropathies (1) · Amyloidosis, Familial (1) · Amyloidosis, Hereditary, Transthyretin-Related (1) · Carpal Tunnel Syndrome (1) · Heart Diseases (1) · Polyneuropathies (1)
Metabolic Diseases (6) · Nutritional and Metabolic Diseases (6) · Proteostasis Deficiencies (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Heredodegenerative Disorders, Nervous System (5) · Metabolism, Inborn Errors (5) · Nervous System Diseases (5) · Neurodegenerative Diseases (5) · Neuromuscular Diseases (5) · Peripheral Nervous System Diseases (5) · Amyloid Neuropathies (4) · Amyloidosis (4) · Amyloidosis, Familial (4) · Immune System Diseases (3)
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · revusiran (1)
Alnylam Pharmaceuticals (2) · AstraZeneca (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Institut Mutualiste Montsouris (1) · Lantheus Germany GmbH (1) · Semmelweis University (1)
Germany (4) · Spain (4) · France (3) · Italy (3) · Portugal (3) · United Kingdom (3) · United States (3) · Denmark (2) · Sweden (2) · Brazil (1) · Bulgaria (1) · Canada (1) · China (1) · Hungary (1) · Israel (1)
Andrew Stephens, MD, PhD (1) · John Vest, MD (1) · Zoltan Pozsonyi, MD, PhD (1)